ERBB2 and breast cancer: Several prospective clinical trials such as KRISTINE, TRAIN-2, and TRYPHENA showed that, compared with traditional NAT based on anthracyclines, NAT based on the combination of paclitaxel and platinum drugs with anti-HER2 drugs (TCbHP) could achieve higher pCR rate, better long-term survival, and lower cardiac toxicity in HER2-positive BC patients (7–9).